Literature DB >> 9735428

Archive selection for the MICAS, a multi-vendor incremental approach to PACS.

E M Smith1, J Wright, M T Fontaine, A Robinson.   

Abstract

From the time a decision was made to purchase an archive until a purchase order was issued took approximately 10 months. During this period an RFI was developed, issued and the results analyzed. Technical discussions were held and site visits were made. To ensure that current information was available, a complete review of available multi-modality DICOM compliant archives were made at the 1997 RSNA. With this information in-hand and the future development path for MICAS specified, a detailed RFQ was developed, responses were received and evaluated. A purchase order was to be issued by the end of the first quarter 1998. The archive vendor will have been selected by the time this paper appears in print. The oral presentation of this work will review the responses of the archive vendors and present the basis for selection. It is planned to publish our findings. The archive is the heart and brains of PACS. It controls information acquisition, distribution and storage plus work flow. It is critical that DICOM compliance and interoperability between all components of the PACS be an absolute requirement, especially for the archive.

Mesh:

Year:  1998        PMID: 9735428      PMCID: PMC3453393          DOI: 10.1007/bf03168254

Source DB:  PubMed          Journal:  J Digit Imaging        ISSN: 0897-1889            Impact factor:   4.056


  2 in total

1.  Integration, acceptance testing, and clinical operation of the Medical Information, Communication and Archive System, phase II.

Authors:  E M Smith; J Wandtke; A Robinson
Journal:  J Digit Imaging       Date:  1999-05       Impact factor: 4.056

2.  The strategic and operational characteristics of a distributed phased archive for a multivendor incremental implementation of picture archiving and communications systems.

Authors:  E M Smith; J Wandtke; A Robinson
Journal:  J Digit Imaging       Date:  1999-05       Impact factor: 4.056

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.